[Phase III additional clinical study of 111In-pentetreotide (MP-1727): diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptors].
Additional phase III multicenter clinical study was performed to investigate the efficacy, safety, and usefulness of somatostatin receptor scintigraphy using 111In-pentetreotide (MP-1727), which binds to somatostatin receptors. Forty patients were included in the study; Group A: 18 patients, gastrointestinal hormone producing tumors had been detected with conventional imaging modalities, Group B: 22 patients, no tumors had been detected with conventional imaging modalities in spite of high serum hormone levels. By comparing the results of the octreotide suppression test, 12/16 cases (75.0%) of Group A and 11/19 cases (57.9%) of Group B were assessed as "effective." By comparing the results of immunohistological examination, 5/9 cases (55.6%) of Group A and 2/4 cases (50.0%) of Group B were assessed as "effective." Severe adverse events were not observed in any of the evaluable 35 cases. MP-1727 was judged as clinically useful in 11/16 cases (68.8%) of Group A and 5/19 cases (26.3%) of group B. These results suggest that MP-1727 scintigraphy is very useful for the diagnosis and decision of the therapeutic strategy of gastrointestinal hormone producing tumors.
Saga
Tsuneo
T
Department of Nuclear Medicine, Kyoto University Faculty of Medicine.
Tamaki
Nagara
N
Itoi
Keiichi
K
Yamazaki
Tetsuro
T
Endo
Keigo
K
Watanabe
Goro
G
Maruno
Hirotaka
H
Machinami
Rikuo
R
Koizumi
Kiyoshi
K
Ichikawa
Taro
T
Takami
Hiroshi
H
Ishibashi
Miyuki
M
Kubo
Atsushi
A
Kusakabe
Kiyoko
K
Hirata
Yukio
Y
Murata
Yuji
Y
Miyachi
Yukitaka
Y
Tsubuku
Masahiko
M
Sakahara
Harumi
H
Katada
Kazuhiro
K
Tonami
Norihisa
N
Yamamoto
Kazutaka
K
Konishi
Junji
J
Imamura
Masayuki
M
Doi
Ryuichiro
R
Shimatsu
Akira
A
Noguchi
Shinzaburo
S
Hasegawa
Yoshinao
Y
Ishikawa
Osamu
O
Watanabe
Yuji
Y
Nakajo
Masayuki
M
D000368:Aged; D005260:Female; D005768:Gastrointestinal Hormones / Q000096:biosynthesis*; D006801:Humans; D007205:Indium Radioisotopes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000378:metabolism
D005768:Gastrointestinal Hormones; D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D013004:Somatostatin; C081788:pentetreotide